Quoin Achieves New Milestone with Further Expansion of Global Netherton Syndrome Clinical Trials
Expansion underscores Company commitment to delivering a globally approved treatment for Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, will extend its ongoing Netherton Syndrome (NS) clinical studies to two additional international sites in London: Great Ormond Street Hospital and St. Thomas’ Hospital. Both hospitals are recognized centers of excellence for treating Netherton Syndrome patients in the UK and have patients potentially eligible to participate in Quoin’s clinical trials. Two ongoing clinical trials are evaluating a topical lotion called QRX003—Quoin’s most advanced pipeline product—to treat Netherton Syndrome, a rare, inherited genetic disease.
In addition, a principal investigator has been appointed and a clinical research organization has been engaged for these studies. The London-based sites and the previously announced Saudi Arabia location will all operate under Quoin’s open Investigational New Drug (IND) application with the U.S. Food and Drug Administration. While preparing to open further sites in other Western European countries, Quoin is concluding a feasibility study in several Eastern European countries; all locations have available cohorts of patients with Netherton Syndrome.
In a press release announcing the news, Quoin CEO Dr. Michael Myers said, “This further international expansion into two highly renowned clinical centers in the United Kingdom, coupled with our intent to open additional sites in other Western European countries as well as in Eastern Europe, underscores our determination and commitment to complete enrollment into both studies as rapidly as possible with a view to potentially delivering the first approved treatment to this underserved patient population.”
Leadership Shows Confidence with Insider Purchases
In a further sign of confidence, Quoin’s CEO Michael Myers and COO Denise Carter recently made significant insider purchases of the company’s shares. On September 3 and 4, 2024, Myers acquired a total of 37,894 ADSs at prices ranging from $0.619 to $0.7974 per ADS. Carter followed suit, purchasing 37,735 ADSs at prices between $0.6253 and $0.7965 per ADS. These purchases signal the leadership’s strong belief in Quoin’s growth trajectory and their commitment to delivering long-term value to shareholders as the company advances its mission.
Earlier this year, Quoin announced the signing of a research agreement with University College Cork in Ireland for the development of potential treatments across a range of range disease indications. In addition, the company announced the planned initiation of an Investigator Study for QRX003 in the rare disease, Peeling Skin Syndrome, which Quoin believes will be the first ever formal clinical study for this indication. Additionally, while actively laying the groundwork to establish its own commercial infrastructure in the US and Western Europe, Quoin continues to grow its worldwide commercialization and distribution network, which now encompasses more than 60 countries, which will enable the Company to market its products on a global basis.
For more information about Quoin’s clinical , please visit https://www.nethertonsyndromeclinicaltrials.com/.
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
